Due tonational shortageof the nebulization solutions, theformulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products willautomatically return to their original formulary status. SeeAlbuterol/Duoneb Shortage Mitigationfor more information. (UpdatedFeb 2023)
The automatic interchange program from albuterol to levalbuterol was discontinued at the August 23, 2006 P&T meeting.
If no specific dose/strength and/or frequency is written, the drug order will be standardized to "levalbuterol 0.63 mg q 8 hours" scheduled, or "0.63 mg q 8 hours prn bronchospasms" for prn orders.
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
The automatic interchange program from albuterol to levalbuterol was discontinued at the August 23, 2006 P&T meeting.
If no specific dose/strength and/or frequency is written, the drug order will be standardized to "levalbuterol 0.63 mg q 8 hours" scheduled, or "0.63 mg q 8 hours prn bronchospasms" for prn orders.
Common Nebulized Doses for Pediatrics
Reviewed: 23 Aug 2006 and 25 Oct 2010 and 25 Mar 2014